ATE420862T1 - 1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung - Google Patents

1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung

Info

Publication number
ATE420862T1
ATE420862T1 AT01936920T AT01936920T ATE420862T1 AT E420862 T1 ATE420862 T1 AT E420862T1 AT 01936920 T AT01936920 T AT 01936920T AT 01936920 T AT01936920 T AT 01936920T AT E420862 T1 ATE420862 T1 AT E420862T1
Authority
AT
Austria
Prior art keywords
production
dihydropyridine compounds
compounds
intermediates
inhibitors
Prior art date
Application number
AT01936920T
Other languages
English (en)
Inventor
Satoshi Nagato
Kohshi Ueno
Koki Kawano
Yoshihiko Norimine
Koichi Ito
Takahisa Hanada
Masataka Ueno
Hiroyuki Amino
Makoto Ogo
Shinji Hatakeyama
Yoshio Urawa
Hiroyuki Naka
Anthony Groom
Leanne Rivers
Terence Smith
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0022483A external-priority patent/GB0022483D0/en
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of ATE420862T1 publication Critical patent/ATE420862T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT01936920T 2000-06-12 2001-06-08 1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung ATE420862T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000175966 2000-06-12
GB0022483A GB0022483D0 (en) 2000-09-13 2000-09-13 1 2 Dihydropyridine compounds manufacturing method thereof and use thereof

Publications (1)

Publication Number Publication Date
ATE420862T1 true ATE420862T1 (de) 2009-01-15

Family

ID=26244997

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01936920T ATE420862T1 (de) 2000-06-12 2001-06-08 1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung

Country Status (27)

Country Link
US (3) US6949571B2 (de)
EP (3) EP2053041A3 (de)
JP (3) JP3922368B2 (de)
KR (3) KR100869271B1 (de)
CN (1) CN1245386C (de)
AT (1) ATE420862T1 (de)
AU (2) AU6272301A (de)
BE (1) BE2013C003I2 (de)
BR (1) BRPI0111596B8 (de)
CA (1) CA2412172C (de)
CY (2) CY1108969T1 (de)
DE (1) DE60137426D1 (de)
DK (1) DK1300396T3 (de)
ES (1) ES2320973T3 (de)
FR (1) FR12C0074I2 (de)
HK (1) HK1056871A1 (de)
HU (2) HU1300187D0 (de)
IL (5) IL152848A0 (de)
LU (1) LU92113I2 (de)
MX (1) MXPA02012314A (de)
NL (1) NL300565I1 (de)
NO (2) NO325160B1 (de)
NZ (1) NZ522773A (de)
PT (1) PT1300396E (de)
TW (2) TW200815402A (de)
WO (1) WO2001096308A1 (de)
ZA (1) ZA200209270B (de)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2320973T3 (es) * 2000-06-12 2009-06-01 EISAI R&D MANAGEMENT CO., LTD. Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos.
US6670380B2 (en) * 2000-11-20 2003-12-30 Bristol-Myers Squibb Co. Pyridone inhibitors of fatty acid binding protein and method
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
JP4119114B2 (ja) * 2001-11-28 2008-07-16 広栄化学工業株式会社 新規なジヒドロキシ（３−ピリジル）ボラン類
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
AU2002351412B2 (en) * 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7101883B2 (en) 2002-03-18 2006-09-05 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases
JP2005529117A (ja) * 2002-04-19 2005-09-29 グラクソ　グループ　リミテッド ５ＨＴ２ｃ受容体に対する親和性を有する化合物及びその治療における使用
JP4208512B2 (ja) * 2002-07-23 2009-01-14 株式会社クラレ ５−（２’−ピリジル）−２−ピリドン誘導体の製造方法
WO2004035563A1 (en) * 2002-10-17 2004-04-29 Syngenta Participations Ag 3-heterocyclylpyridine derivatives useful as herbicides
EA009027B1 (ru) * 2002-12-16 2007-10-26 Мицубиси Фарма Корпорейшн Производные 3-замещенного-4-пиримидона
EP1581539A4 (de) * 2003-01-03 2007-09-19 Bristol Myers Squibb Co Neue tyrosinkinase-hemmer
GB0305024D0 (en) * 2003-03-05 2003-04-09 Glaxo Group Ltd Compounds
SE0302324D0 (sv) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302323D0 (sv) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
EP2522670A1 (de) * 2004-04-07 2012-11-14 Takeda Pharmaceutical Company Limited Heterozyklische CRF-Rezeptor-Antagonisten
MY148809A (en) * 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
JP2007099781A (ja) * 2004-07-06 2007-04-19 Eisai R & D Management Co Ltd １，２−ジヒドロピリジン化合物の結晶の製造方法
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
WO2006065946A1 (en) * 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
WO2006074419A2 (en) * 2005-01-07 2006-07-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
AU2006232517A1 (en) * 2005-04-04 2006-10-12 Eisai R&D Management Co., Ltd. Dihydropyridine compounds and compositions for headaches
AU2006234627C1 (en) * 2005-04-08 2009-11-26 Eisai R & D Management Co., Ltd. Therapeutic agent for dyskinesia
RS53599B1 (en) 2005-05-10 2015-02-27 Intermune, Inc. PIRIDON DERIVATIVES FOR STRESS MODULATION OF ACTIVATED PROTEIN KINASE SYSTEMS
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
MX2008001538A (es) * 2005-08-02 2008-04-04 Lexicon Pharmaceuticals Inc Aril piridinas y metodos para su uso.
JP2009506123A (ja) 2005-08-29 2009-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド 非受容体型チロシンキナーゼのｔｅｃファミリーの阻害剤として有用な３，５−二置換ピリド−２−オン
CN101291926A (zh) * 2005-08-29 2008-10-22 沃泰克斯药物股份有限公司 可用作Tec家族非受体酪氨酸激酶抑制剂的3,5-二取代的吡啶-2-酮
AU2006285038A1 (en) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases
RU2008112691A (ru) 2005-10-03 2009-10-10 Оно Фармасьютикал Ко., Лтд. (Jp) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
JPWO2007072868A1 (ja) * 2005-12-21 2009-06-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 １，２−ジヒドロピリジン化合物の結晶（ｉｖ型）
JPWO2007072869A1 (ja) * 2005-12-21 2009-06-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 １，２−ジヒドロピリジン化合物の非晶質体
JP4865337B2 (ja) * 2006-01-24 2012-02-01 富士フイルムファインケミカルズ株式会社 ２，３’−ビピリジル−６’−オンの製造方法
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
WO2007126060A1 (ja) * 2006-04-28 2007-11-08 Eisai R & D Management Co., Ltd １，２－ジヒドロピリジン化合物の塩
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
US20080108603A1 (en) * 2006-10-19 2008-05-08 Eisenach James C Combination therapy for the treatment of pain
US20080108622A1 (en) * 2006-10-19 2008-05-08 Eisenach James C Combination therapy for the treatment of pain
JP2010520154A (ja) * 2007-03-05 2010-06-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経変性疾患のためのａｍｐａレセプターアンタゴニストおよびｎｍｄａレセプターアンタゴニスト
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
WO2008139984A1 (en) * 2007-04-26 2008-11-20 Eisai R & D Management Co., Ltd. Cinnamide compounds for dementia
EP2164488A1 (de) * 2007-07-13 2010-03-24 Eisai R&D Management Co., Ltd. Ampa-rezeptor-antagonisten und aldose-reduktase-hemmer für neuropathische schmerzen
CA2690110A1 (en) * 2007-07-13 2009-01-22 Eisai R&D Management Co., Ltd. Ampa receptor antagonists for neuropathic pain
US8252937B2 (en) 2007-09-14 2012-08-28 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
BRPI0816767B8 (pt) 2007-09-14 2021-05-25 Addex Pharmaceuticals Sa composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
AU2008297877C1 (en) 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
WO2009054544A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
TW200924770A (en) * 2007-11-06 2009-06-16 Astrazeneca Ab Novel compounds 089
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2009081872A1 (ja) 2007-12-21 2009-07-02 Kuraray Co., Ltd. ６－ハロゲノ－３－アリールピリジン誘導体の製造方法
WO2009082038A2 (en) * 2007-12-26 2009-07-02 Eisai R & D Management Co., Ltd. Ampa receptor antagonists and zonisamide for epilepsy
JP2011507800A (ja) * 2007-12-26 2011-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 癲癇、精神障害、または感覚器官の障害のためのａｍｐａ受容体アンタゴニスト
CN102083794A (zh) * 2008-05-05 2011-06-01 安姆根有限公司 作为γ分泌酶调节剂的脲化合物
CA2726588C (en) * 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
US8859760B2 (en) 2008-07-29 2014-10-14 Frontier Scientific, Inc. Compositions for killing or preventing the growth of microbes
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
EP2346505B1 (de) 2008-10-16 2014-04-23 Janssen Pharmaceuticals, Inc. Indol- und benzomorpholinderivate als modulatoren von metabotropen glutamatrezeptoren
CA2741666C (en) * 2008-10-31 2017-04-11 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
CA2745866A1 (en) 2008-12-23 2010-07-01 F.Hoffmann-La Roche Ag Dihydropyridone ureas as p2x7 modulators
SG172336A1 (en) 2008-12-23 2011-07-28 Hoffmann La Roche Dihydropyridone amides as p2x7 modulators
SG172785A1 (en) 2008-12-23 2011-08-29 Hoffmann La Roche Dihydropyridone amides as p2x7 modulators
WO2010072607A1 (en) 2008-12-23 2010-07-01 F. Hoffmann-La Roche Ag Dihydropyridone amides as p2x7 modulators
US8153808B2 (en) 2008-12-23 2012-04-10 Roche Palo Alto Llc Dihydropyridone amides as P2X7 modulators
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
US8410144B2 (en) 2009-03-31 2013-04-02 Arqule, Inc. Substituted indolo-pyridinone compounds
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BR112012007322A2 (pt) 2009-10-02 2017-06-06 Astrazeneca Ab composto de 2-piridona usados como inibidores de neutrófilo elastase
JP2013234123A (ja) * 2010-09-03 2013-11-21 Taisho Pharmaceutical Co Ltd ３−ピラゾリル−２−ピリドン誘導体
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
PL2648516T3 (pl) * 2010-12-06 2019-04-30 Aclaris Therapeutics Inc Podstawione związki pirydynono-pirydynylowe
EP3434669B1 (de) 2011-03-04 2020-11-04 Yale University In der synthese von ( )-huperzin verwendbare zwischenproduktverbindungen und verfahren zur herstellung eine dieser zwischenproduktverbindungen
ITMI20111952A1 (it) 2011-10-27 2013-04-28 Italiana Sint Spa Procedimento per la prepazione di 2-metossi-5-(piridin-2-il)piridina, un intermedio del perampanel
WO2013102897A1 (en) 2012-01-03 2013-07-11 Mapi Pharma Ltd. Polymorphs of perampanel
EP2831056B1 (de) * 2012-03-31 2016-12-14 The University Of Georgia Research Foundation, Inc Neue antimykobakterielle arzneimittel gegen tuberkulose
AU2013292950C1 (en) * 2012-07-18 2016-01-21 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
ITMI20121390A1 (it) 2012-08-06 2014-02-07 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di acido 2-cianofenilboronico e suoi esteri, intermedi del perampanel o di e2040
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
TW201441193A (zh) 2012-12-06 2014-11-01 Kyowa Hakko Kirin Co Ltd 吡啶酮化合物
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
JP2016522786A (ja) * 2013-04-04 2016-08-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ［１１ｃ］及び［１８ｆ］標識化１，３−ジフェニルー５−（ピリミジン−２−イル）−ピリジン−２（１ｈ）−オン誘導体並びにａｍｐａ受容体のｐｅｔイメージングのためのそれらの使用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
CN103274993A (zh) * 2013-06-13 2013-09-04 南京工业大学 二氢吡啶和吡咯类杂环的新合成方法
ES2646095T3 (es) * 2013-07-25 2017-12-12 Teva Pharmaceuticals International Gmbh Proceso para la preparación de perampanel
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
US9120777B2 (en) 2013-10-29 2015-09-01 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN103664756A (zh) * 2013-11-26 2014-03-26 苏州晶云药物科技有限公司 吡仑帕奈新晶型a及其制备方法
CN104706604A (zh) * 2013-12-12 2015-06-17 北京星昊医药股份有限公司 一种吡仑帕奈冻干口崩片及其制备方法
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
DK3431106T3 (da) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
DK3096790T3 (da) 2014-01-21 2019-10-07 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
CN105085382B (zh) * 2014-05-14 2019-10-18 江苏豪森药业集团有限公司 吡仑帕奈异构体晶型及其制备方法和用途
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
CN103980188B (zh) * 2014-05-30 2016-01-27 浙江永宁药业股份有限公司 一种吡仑帕奈的合成方法及其中间体和中间体的合成方法
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
US10227328B2 (en) * 2015-02-04 2019-03-12 Beyondbio Inc. Heterocyclic compound and pharmaceutical composition comprising same
US10111867B2 (en) 2015-02-17 2018-10-30 Mapi Pharma Ltd. Process and intermediates for the preparation of perampanel
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
WO2016172333A1 (en) 2015-04-21 2016-10-27 Teva Pharmaceuticals International Gmbh A solid state form of perampanel
RU2705595C2 (ru) 2015-07-06 2019-11-11 Паблик Юниверсити Корпорейшн Йокогама Сити Юниверсити Новое соединение, специфически связывающееся с рецептором ampa
CN105085383B (zh) * 2015-08-19 2017-09-01 四川大学 5‑甲基‑2(1h)吡啶酮衍生物及其制备方法和用途
CA3002930A1 (en) 2015-11-13 2017-05-18 Eisai R&D Management Co., Ltd. Pyranodipyridine compound
KR101652750B1 (ko) * 2015-12-03 2016-08-31 김종선 피리딘 및 그 유도체의 정제방법
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
EP3541785A4 (de) 2016-11-18 2020-04-01 Dow Agrosciences Llc 4-((6-bromopyridin-3-yl)oxy)benzonitril und verfahren zur herstellung
WO2018114989A1 (en) * 2016-12-22 2018-06-28 Biotronik Ag Intratumoral drug delivery materials and methods for treating breast cancer
JP6241974B1 (ja) 2017-01-11 2017-12-06 公立大学法人横浜市立大学 霊長類生体の脳内ａｍｐａ受容体のイメージング方法、プログラム、及びスクリーニング方法
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
CA3108048A1 (en) * 2017-07-31 2019-02-07 Washington University Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
CN110028442B (zh) * 2018-01-11 2020-07-17 新发药业有限公司 一种吡仑帕奈的简便制备方法
GB201803340D0 (en) * 2018-03-01 2018-04-18 Univ Of Sussex Compounds
EP3560934A1 (de) 2018-04-26 2019-10-30 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Verfahren zur herstellung von reiner 2-cyanophenylboronsäure und deren ester, zwischenprodukte von perampanel oder e2040
KR20210107644A (ko) 2018-12-14 2021-09-01 에자이 알앤드디 매니지먼트 가부시키가이샤 1,2-디하이드로피리딘 화합물의 수성 기반 약학적 제형
CN110483563B (zh) * 2019-09-06 2021-12-28 山西医科大学 一种新型离子型β-萘酚醛席夫碱锆配合物的制备方法及应用
KR102392825B1 (ko) 2020-02-18 2022-04-29 명인제약주식회사 2-(2-옥소-1-페닐-5-피리딘-2-일피리딘-3-일)벤조니트릴과 ｌ-말릭산의 공결정 화합물 및 이의 제조 방법
CN111362930B (zh) * 2020-04-15 2023-02-03 安徽医科大学 一种1，2，4-噁二唑-吡啶类化合物及其应用
WO2023042887A1 (ja) 2021-09-15 2023-03-23 国立大学法人 琉球大学 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物
WO2023042888A1 (ja) 2021-09-15 2023-03-23 国立大学法人 琉球大学 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物
CN114057630B (zh) * 2021-12-23 2023-06-02 郑州大学 吡非尼酮衍生物及其合成方法和应用
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2024010585A1 (en) * 2022-07-07 2024-01-11 Yale University Non-covalent inhibitors of the main protease of sars-cov-2 and methods of use
KR20240008565A (ko) * 2022-07-12 2024-01-19 이화여자대학교 산학협력단 연속 흐름 공정을 포함하는 페람파넬 유도체의 제조 방법
US11958832B1 (en) 2023-10-12 2024-04-16 King Faisal University 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitriles as antimicrobial compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283761A (en) * 1976-01-01 1977-07-12 Yamanouchi Pharmaceut Co Ltd Novel pyridone derivative
JPS5531072A (en) * 1979-07-30 1980-03-05 Rikagaku Kenkyusho Preparation of 2-pyridone compound
DE4003541C1 (de) 1990-02-06 1991-08-08 Alter S.A., Madrid, Es
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
IL109397A0 (en) 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HU219777B (hu) 1993-07-02 2001-07-30 Gyógyszerkutató Intézet Kft. Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására
MX9702244A (es) 1994-09-27 1997-06-28 Yamanouchi Pharma Co Ltd Derivado de 1,2,3,4-tetrahidroquinoxalinadiona.
EP0826671B1 (de) * 1995-04-27 2004-12-29 Mitsubishi Pharma Corporation Heterocyclische amidverbindungen und deren medizinische verwendung
US5935551A (en) 1995-11-15 1999-08-10 California Institute Of Technology Synthesis of zeolites by hydrothermal reaction of zeolite P1
DE19604920A1 (de) 1996-02-01 1997-08-07 Schering Ag Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
US5891871A (en) 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
HU9600871D0 (en) 1996-04-04 1996-05-28 Gyogyszerkutato Intezet New 2,3-benzodiazepine derivatives
PT901487E (pt) 1996-05-15 2003-08-29 Pfizer 4(3h)-quinazolinonas 2,3,6-trissubstituidas
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
IL130181A0 (en) 1996-12-05 2000-06-01 Amgen Inc Substituted pyrimidone and pyridone compounds and methods of use
HUP0000914A3 (en) 1997-02-28 2001-09-28 Pfizer Prod Inc Atropisomers of 3-aryl-4(3h)-quinazolinones and pharmaceutical compositions containing them
GB9708945D0 (en) * 1997-05-01 1997-06-25 Merck Sharp & Dohme Therapeutic agents
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
WO1999031062A1 (fr) * 1997-12-17 1999-06-24 Shionogi & Co., Ltd. Nouveaux composes de pyridine
WO2000001376A2 (en) 1998-07-02 2000-01-13 Eisai Co., Ltd Pharmaceutical compositions and their uses for treatment of demyelinating disorders
DE19835918A1 (de) 1998-08-07 2000-02-10 Dresden Arzneimittel Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung
ES2320973T3 (es) 2000-06-12 2009-06-01 EISAI R&D MANAGEMENT CO., LTD. Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos.
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses

Also Published As

Publication number Publication date
NZ522773A (en) 2005-06-24
US7563811B2 (en) 2009-07-21
AU2001262723C1 (en) 2006-05-11
IL184687A (en) 2010-06-30
AU2001262723B2 (en) 2005-05-12
EP1300396B1 (de) 2009-01-14
PT1300396E (pt) 2009-04-20
EP2177520A1 (de) 2010-04-21
IL184687A0 (en) 2007-12-03
DK1300396T3 (da) 2009-04-06
NO2012021I2 (no) 2013-09-09
JP5068069B2 (ja) 2012-11-07
EP2053041A2 (de) 2009-04-29
KR20070094995A (ko) 2007-09-27
TWI292757B (de) 2008-01-21
ES2320973T3 (es) 2009-06-01
BR0111596A (pt) 2004-03-02
IL184686A (en) 2010-05-17
US7939549B2 (en) 2011-05-10
HUP0303398A2 (hu) 2004-03-01
KR20030012882A (ko) 2003-02-12
US6949571B2 (en) 2005-09-27
TWI321565B (de) 2010-03-11
KR100904011B1 (ko) 2009-06-22
IL192605A (en) 2012-06-28
NL300565I2 (de) 2016-01-18
CY2012032I2 (el) 2015-08-05
HU229553B1 (en) 2014-01-28
ZA200209270B (en) 2005-08-31
JP2007119486A (ja) 2007-05-17
KR20070094994A (ko) 2007-09-27
CY2012032I1 (el) 2014-07-02
CA2412172A1 (en) 2002-12-06
TW200815402A (en) 2008-04-01
NO325160B1 (no) 2008-02-11
BE2013C003I2 (de) 2020-08-20
FR12C0074I2 (fr) 2013-08-16
CN1245386C (zh) 2006-03-15
EP2053041A3 (de) 2009-07-29
JPWO2001096308A1 (ja) 2004-01-08
NO20025955L (no) 2003-02-12
IL152848A0 (en) 2003-06-24
FR12C0074I1 (de) 2013-01-18
DE60137426D1 (de) 2009-03-05
CA2412172C (en) 2012-07-24
CN1436172A (zh) 2003-08-13
NO2012021I1 (no) 2013-01-07
KR100869271B1 (ko) 2008-11-18
US20090275751A1 (en) 2009-11-05
BRPI0111596B8 (pt) 2022-07-26
EP1300396A1 (de) 2003-04-09
HU1300187D0 (hu) 2004-03-01
US20050245581A1 (en) 2005-11-03
EP1300396A4 (de) 2005-06-15
IL184686A0 (en) 2007-12-03
IL152848A (en) 2007-09-20
US20040023973A1 (en) 2004-02-05
NO20025955D0 (no) 2002-12-11
WO2001096308A1 (fr) 2001-12-20
BRPI0000596B8 (pt) 2021-05-25
NL300565I1 (de) 2016-01-18
MXPA02012314A (es) 2004-09-06
KR100850728B1 (ko) 2008-08-06
HUP0303398A3 (en) 2010-03-29
CY1108969T1 (el) 2014-07-02
BRPI0111596B1 (pt) 2018-10-02
JP2012207021A (ja) 2012-10-25
IL192605A0 (en) 2009-02-11
LU92113I2 (fr) 2013-02-12
JP3922368B2 (ja) 2007-05-30
HK1056871A1 (en) 2004-03-05
AU6272301A (en) 2001-12-24

Similar Documents

Publication Publication Date Title
ATE420862T1 (de) 1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung
DE69923300D1 (de) Cycloalken-derivate, verfahren zu ihrer herstellung und ihre verwendung
NO20033385D0 (no) Fuserte heterocykliske forbindelser
DE60318583D1 (de) N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung
ATE137500T1 (de) Substituierte pyridinsulfonamidverbindungen, diese enthaltende herbizide zusammensetzungen und verfahren zu ihrer herstellung
CO5690587A2 (es) Derivados de acido bensoilureidopiridil-piperidin-y pirrolidin carboxilico sustituido, metodo para su produccion y su uso
DE50204181D1 (de) Phthalsäurediamide, ein verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
DE60310609D1 (de) Verfahren zur herstellung von 2-aminomethylpyridin-derivaten
DE69725167D1 (de) N-benzolsulfonyl-l-prolin derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung
EA200100155A3 (ru) Новые производные 6-амино или 6-гидразиносульфонил-3-хинолинилфосфоновой кислоты, способ их получения и содержащие их фармацевтические композиции
HUP0104045A2 (hu) Eljárás 4-[(2',5'-diamino-6'-halogén-pirimidin-4'-il)-amino]-ciklopent-2-enilmetanol-származékok előállítására
DE60304327D1 (de) 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINOi4,5-BöINDOLACETAMIDDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE THERAPEUTISCHE VERWENDUNG
ATE264314T1 (de) Benzoxazol-derivate, verfahren zu ihrer herstellung und herbizide
HUP0003497A2 (hu) Eljárás szubsztituált 2-nitro-guanidin-származékok és intermedierjeik előállítására
DE50107619D1 (de) Verfahren zur herstellung von 4-brom-anilin-derivaten
FR2800373B1 (fr) Procede de preparation d'oxazoles trisubstitues

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1300396

Country of ref document: EP